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Abstract
Background: Red cell distribution width (RDW) is an indicator of erythrocyte in different 
size, and its prognostic value has been demonstrated in numerous cardiac and non-cardiac 
diseases. The purpose of this study was to evaluate the predictive value of RDW on the long- 
-term cardiovascular events in patients undergoing primary percutaneous coronary interven-
tion (PCI).
Methods: Ninety-six consecutive patients (mean age 60.6 ± 12.5 years, 77.1% male) with 
ST-segment elevation myocardial infarction (STEMI), who were treated with primary PCI, 
were analyzed prospectively. Baseline RDW and high sensitive C-reactive protein (hs-CRP) 
were measured. The patients were followed up for major adverse cardiac events (MACE) for 
up to 48 months after discharge.
Results: There were 30 patients with long-term MACE (Group 1) and 66 patients without 
long-term MACE (Group 2). Age, admission RDW, hs-CRP and creatine kinase-MB levels, 
heart rate after PCI, previously used angiotensin converting enzyme inhibitor, left anterior de-
scending artery lesion, and electrocardiographic no-reflow were higher in Group 1. Admission 
hemoglobin levels were lower in Group 1. An RDW level ≥ 13.85% measured on admission 
had 80% sensitivity and 64% specificity in predicting long-term MACE on receiver-operating 
characteristic curve analysis. In multivariate analyses, only admission RDW (HR 5.26,  
< 95% CI 1.71–16.10; p = 0.004) was an independent predictor of long-term MACE.
Conclusions: A high baseline RDW value in patients with STEMI undergoing primary PCI 
is independently associated with increased risk for long term MACE. (Cardiol J 2016; 23, 3: 
281–288)
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Introduction
It is recommended to immediately re-perfuse 
the culprit artery with primary percutaneous coro-
nary intervention (PCI) in ST-segment elevation 
myocardial infarction (STEMI). Despite significant 
prognostic improvements with newer treatment 
approaches and strategies in STEMI patients, 
incidence of adverse cardiovascular events (CVE) 
still remains significant in high risk patients both 
in hospital and long-term follow-up. Therefore, 
identification of the high-risk patients may have 
a leading role in application of additional pharma-
cological and mechanical treatment approaches 
providing prognostic benefits during and after the 
primary PCI. There are many studies in the litera-
ture showing that besides numerous demographic 
and clinical features, increased inflammation and 
oxidative stress are important determinants of 
prognosis in STEMI.
Red cell distribution width (RDW) is a rou-
tinely used measure as part of a standard complete 
blood count (CBC) in clinical practice. RDW which 
is a measure of the variation in the size of circulat-
ing erythrocytes (anisocytosis) has been utilized 
in differential diagnosis of anemia [1]. In addition, 
increased levels of RDW are closely associated with 
inflammation [2–4], oxidative stress [5] and are 
related with poor prognoses in stable and unstable 
cardiac events [6–9].
Although a few studies have investigated the 
prognostic significance of RDW in STEMI patients, 
these studies were either retrospective or had 
a short follow-up. To the best of our knowledge, this 
is the first prospective study with longer follow-
up time, investigating prognostic value of RDW 
in STEMI patients who underwent primary PCI.
Methods
Study population
A total of 135 patients with STEMI who under-
went cardiac catheterization between September 
2010 and December 2010 were included in this 
study. The patients who presented within 12 h (18 h 
for cardiogenic shock) of the onset of symptoms 
(typical chest pain lasting for > 30 min) and having 
a ST-segment elevation ≥ 1 mm in at least two 
adjacent electrocardiography (ECG) leads were 
included in the study. We had to exclude some 
patients due to various reasons: 17 patients were 
excluded from the study because they had not 
undergone primary PCI and were treated conserva-
tively or referred to surgery, 8 patients in whom 
we were unable to obtain long-term follow-up data, 
4 patients due to a left ventricular hypertrophy result 
on baseline ECG which was defined as Sokolow-
Lyon voltages > 35 mV, 4 patients because of 
the presence of anemia at the time of admission, 
2 patients due to new onset of complete left bundle 
branch block, 2 patients because of non-cardiac 
death, and 2 patients because they had been given 
thrombolytic therapy before the primary PCI. As 
a result, 96 non-anemic patients (77.1% male and 
mean age 60.6 ± 12.5) with primary PCI were en-
rolled in the study. Patients were divided into two 
groups: 30 patients with long-term major adverse 
cardiac events (MACE, Group 1) and 66 patients 
without long-term MACE (Group 2). The study 
was approved by the Ethical Committee of our 
hospital; signed and informed written consents 
were received from all the patients included.
Definitions
Clinical characteristics of patients were re-
corded including age and gender, hypertension, 
hypercholesterolemia, diabetes mellitus (DM), 
history of coronary artery disease (CAD), smoking 
status, height, and weight. The body mass index 
was calculated by dividing body mass in kilograms 
by the square of the height in m2 (kg/m2). The di-
agnosis of DM was set based on previous history 
of DM treated with or without medication. Hyper-
cholesterolemia was defined as total cholesterol 
≥ 200 mg/dL. Reperfusion time was defined as the 
time between onset of chest pain and inflation of 
the first balloon. Multi-vessel disease was defined 
as a stenosis > 50% in 2 or more major epicardial 
coronary arteries. A successful intervention was 
defined as a reduction in stenosis or obstruction 
to less than 50% with Thrombolysis in Myocar-
dial Infarction (TIMI) 2–3 flow after primary PCI. 
Premature discontinuation of clopidogrel therapy 
was defined as continued dual antiplatelet therapy 
for less than 1 year. Anemia on admission was de-
fined according to the World Health Organization 
as baseline hemoglobin (Hb) value < 13 mg/dL in 
men and < 12 mg/dL in women.
Coronary angiography and PCI procedure
Primary PCI procedure was carried out through 
standard femoral approach using a 7-French guid-
ing catheter. After administration of 10,000 IU of 
heparin, 300 mg acetylsalicylic acid (ASA) and 
600 mg clopidogrel loading dose conventional 
wire crossing, direct stenting (bare metal stents) 
was performed whenever possible, while balloon 
pre-dilatation was carried out in the remaining 
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cases. Tirofiban was given concomitantly with the 
primary PCI, depending on operator’s decision. 
Non-ionic low osmolality contrast agent was used 
in all patients. After angioplasty, all patients were 
admitted to the coronary care unit; 100 mg ASA and 
75 mg clopidogrel were continued for all patients. 
Concomitant medical treatment with beta-blockers, 
angiotensin converting enzyme inhibitors (ACEI), 
and statins was prescribed according to American 
College of Cardiology/American Heart Association 
guidelines.
Laboratory analysis, ECG  
and echocardiography
In all patients, antecubital venous blood sam-
ples were collected in the emergency room for the 
laboratory analysis during admission. Hemoglobin, 
RDW and white blood cell count, as well as other 
hematologic indices, were measured as part of 
the CBC, using a Coulter LH 780 Hematology 
Analyzer (Beckman Coulter Ireland Inc., Mervue, 
Galway, Ireland). High sensitive C-reactive protein 
(hs-CRP) was measured through a BN2 model 
nephelometer (Dade-Behring).
Measurements were taken from the first ECG 
which was ordered immediately before angioplasty 
(STE 1) and from the second ECG which was 
obtained 60 min after PCI (STE 2). The sum of 
ST-segment elevation (sum STE) was calculated 
by adding all ST elevations present in leads I, aVL 
and V1 through V6 for anterior and in leads II, III, 
aVF, V5 and V6 for inferior infarctions [10]. The 
difference between STE 1 and STE 2 was then 
measured and accepted as the resolution of the sum 
of ST-segment elevation, expressed as sigma STR 
(∑STR). Patients with ∑STR < 50% were consid-
ered having electrocardiographic no-reflow phe-
nomenon, based on the classification by Schroder 
et al. [11]. Transthoracic echocardiography was 
performed in all patients in the intensive cardiac 
care unit immediately after primary PCI through 
a system V (Vingmed; GE, Horten, Norway) using 
a 2.5 MHz phased-array transducer. Measurements 
were were taken on patients at the position of left 
lateral decubitus. The left ventricular ejection frac-
tion was measured using the modified Simpson’s 
rule [12].
Clinical endpoints
All the patients were prospectively followed 
up for 48 months, and the evaluations in 48th month 
were performed either on-site or via phone. The 
main endpoints assessed in this study included the 
MACE that were defined as cardiovascular mortal-
ity, repeat target vessel revascularization (TVR) 
and reinfarction (re-MI). Cardiovascular mortality 
in patients was defined as death attributable to 
myocardial ischemia and infarction, heart failure, 
arrhythmia (ventricular fibrillation, ventricular 
tachycardia or asystole) and cardiac arrest because 
of other or unknown cause or cerebrovascular 
accident. TVR was defined as the requirement of 
PCI or coronary surgery in the target vessel driven 
by clinical symptoms such as the restenosis or 
re-occlusion of the infarct related artery. Re-MI 
was defined as a re-elevation in creatine kinase 
(CK) that was twice as high of the last value as-
sociated with CK-MB ≥ 10% of the total CK and 
ST-segment re-elevations [13].
Statistics analysis
Continuous variables are expressed as mean 
± standard deviation, while categorical variables 
are given as percentages. The Student’s t-test 
was used in comparison of parametric continuous 
variables, Mann-Whitney U test in comparison 
of nonparametric continuous variables and the 
c2 test for comparison of categorical variables. 
The cumulative survival curves for long-term 
MACE were constructed using the Kaplan-Meier 
method, while log-rank testing was used in evalu-
ation of the differences between the RDW groups. 
Sensitivity and specificity of RDW, as well as its 
respective optimal cut-off value in prediction 
long-term MACE, were expressed through the 
receiver operating characteristics (ROC) curve. 
Multivariate Cox regression analysis was used 
in order to define the independent predictors of 
long-term MACE. All variables which showed 
significance values < 0.1 on univariate analysis 
were included in the model. The RDW level 
was adjusted with Hb and all covariates in the 
Cox regression analysis. Two-tailed p values 
< 0.05 were considered statistically significant in 
a confidence interval (CI) of 95%. Statistical 
analyses were performed using the SPSS software 
(version 15.0, SPSS, Chicago, Illinois, USA).
Results
There were 30 patients (mean age 64.5 ± 12.4, 
76.7% male) in Group 1 and 66 patients (mean age 
58.9 ± 12.3, 77.3% male) in Group 2. Baseline 
characteristics are shown in Table 1. Patients in 
the Group 1 were significantly older (p = 0.03). 
There were no significant differences between 
the groups with regard to cardiovascular risk fac-
tors. With respect to baseline laboratory status, 
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Table 1. Baseline characteristics of patients with and without long-term major adverse cardiac events 
(MACE).
Group 1 (n = 30) Group 2 (n = 66) P
Age [years] 64.5 ± 12.4 58.9 ± 12.3 0.03
Male gender 23 (76.7%) 51 (77.3%) 0.57
Hypertension 13 (43.3%) 20 (30.3%) 0.16
Diabetes mellitus 4 (13.3%) 12 (18.2%) 0.39
Hypercholesterolemia 9 (30.0%) 20 (30.3%) 0.59
Smoking 15 (50.0%) 38 (57.6%) 0.32
Previous CAD 6 (20.0%) 13 (19.7%) 0.59
Body mass index [kg/m2] 25.9 ± 5.2 26.6 ± 3.7 0.34
Hs-CRP [mg/dL] 12.1 ± 10.2 6.06 ± 5.4 0.003
LVEF on admission [%] 42.3 ± 9.5 43.6 ± 10.9 0.48
Serum glucose [mg/dL] 154.3 ± 76.6 155.5 ± 68.0 0.83
Admission CK-MB [U/L] 148.51 ± 123.54 86.76 ± 93.03 0.005
Hemoglobin [g/dL] 14.7 ± 2.1 15.8 ± 1.4 0.01
Platelet [mm3] 248.0 ± 64.9 250.2 ± 63.9 0.89
White blood cell [103/μL] 12.5 ± 4.1 12.3 ± 4.2 0.76
Mean platelet volume [fL] 8.2 ± 1.1 8.0 ± 1.0 0.42
Red cell distribution width [%] 14.9 ± 1.3 13.6 ± 0.6 < 0.001
Hemodynamic data pre-PCI:
Systolic BP [mm Hg] 133.7 ± 26.5 132.7 ± 30.9 0.72
Diastolic BP [mm Hg] 84.1 ± 16.5 86.6 ± 16.0 0.31
Heart rate [bpm] 86.5 ± 19.7 79.9 ± 20.7 0.11
Hemodynamic data after PCI
Systolic BP [mm Hg] 118.5 ± 32.7 119.8 ± 22.5 0.72
Diastolic BP [mm Hg] 77.8 ± 17.4 77.5 ± 17.4 0.80
Heart rate [bpm] 85.3 ± 15.8 76.9 ± 17.8 0.03
Creatinine [mg/dL] 0.91 ± 0.26 0.87 ± 0.24 0.33
Uric acid [mg/dL] 4.7 ± 2.1 4.8 ± 1.4 0.31
Previous medications: 
Acetylsalicylic acid 6 (20.0%) 9 (13.6%) 0.30
Beta-blockers 2 (6.7%) 7 (10.6%) 0.42
ACEI 8 (26.7%) 6 (9.1%) 0.03
Statin therapy 1 (3.3%) 4 (6.1%) 0.50
Diuretic 1 (3.3%) 2 (3.0%) 0.68
Calcium channel blockers 3 (10.0%) 4 (6.1%) 0.38
Long term medications:
Acetyl-salicylic acid 27 (90%) 62 (93.4%) 0.38
Premature discontinuation of clopidogrel therapy 5 (16.7%) 3 (4.6%) 0.06
Beta-blockers 20 (66.7%) 47 (71.2%) 0.41
ACEI 19 (63.3%) 43 (65.2%) 0.51
Statin therapy 18 (60%) 42 (63.6%) 0.45
Diuretic 11 (36.7%) 23 (34.8%) 0.51
Calcium channel blockers 13 (43.3%) 26 (39.4%) 0.44
Multivessel disease 19 (63.3%) 31 (47.0%) 0.10
Infarct related artery: 0.04
LAD 19 (63.3%) 27 (40.9%)
CX 6 (20%) 8 (12.1%)
RCA 5 (16.7%) 31 (47%)
Reperfusion time [h] 4.7 ± 2.1 4.6 ± 1.9 0.73
Stent implanted 27 (90.0%) 59 (89.4%) 0.62
Stent length [mm] 17.9 ± 5.7 19.9 ± 6.1 0.16
Stent diameter [mm] 3.05 ± 0.25 3.13 ± 0.29 0.31
Tirofiban administered 23 (76.7%) 44 (66.7%) 0.23
Electrocardiographic no-reflow 14 (46.7%) 15 (22.7%) 0.02
Angiographic failure 7 (23.3%) 6 (9.1%) 0.06
Cardiovascular mortality 20 (66.7%)
Repeat target vessel revascularization 15 (50%)
Reinfarction 20 (66.7%)
Data are expressed as mean ± standard deviation for continuous variables and percentages n (%) for categorical variables; CAD — coronary 
artery disease; hs-CRP — high sensitive C reactive protein; LVEF — left ventricular ejection fraction; CK-MB — creatinine kinase-MB;  
PCI — percutaneous coronary intervention; BP — blood pressure; ACEI — angiotensin converting enzyme inhibitors; LAD — left anterior de-
scending; CX — circumflex coronary artery; RCA — right coronary artery; Group 1 — patients with MACE; Group 2 — patient without MACE
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while admission hs-CRP (p = 0.003), CK-MB 
(p = 0.005) and RDW (p < 0.001) were signifi-
cantly higher in Group 1, admission Hb was sig-
nificantly lower (p = 0.01). Heart rate after PCI 
(p = 0.03), previously used an ACEI (p = 0.03), 
left anterior descending artery lesion (p = 0.03) 
and electrocardiographic no-reflow (p = 0.02) 
were significantly higher in Group 1. There were 
20 (66.7%) patients with cardiovascular mortality, 
15 (50%) patients with TVR and 20 (66.7%) pa-
tients with re-MI in Group I patients.
The ROC curves of RDW for predicting 
long-term MACE is shown in Figure 1. A RDW 
≥ 13.85% measured on admission had 80% sensi-
tivity and 64% specificity in predicting long-term 
MACE.
In the multivariate analyses for long-term 
MACE, age, Hb, RDW, hs-CRP, CK-MB on admis-
sion, previously used an ACEI, premature discon-
tinuation of clopidogrel therapy, heart rate after PCI, 
left anterior descending artery lesion, presence of 
electrocardiographic no-reflow, and angiographic 
failure were analyzed with multivariate Cox re-
gression model. Only RDW (HR 5.26, < 95% CI 
1.71–16.10, p = 0.004) was still independent predic-
tors of long-term MACE, even after adjustment for 
Hb (Tables 2, 3). Kaplan-Meier survival plots for 
MACE in RDW groups are presented in Figure 2.
Discussion
This is the first prospective study investigat-
ing the relationship between the admission levels 
of RDW and long-term CVE in STEMI patients who 
underwent primary PCI. In the present study, we 
demonstrated that a higher baseline RDW levels 
were an independent predictor of 48-month cardio-
vascular outcomes in STEMI patients.
Red cell distribution width, which is a part 
of standard CBC, is a quantitative measure of the 
variations in the size of circulating erythrocytes. 
Clinical use of RDW has usually been confined to 
the differential diagnosis of anemia and hemato-
logical disorders. Elevated RDW typically indicates 
increased destruction of red cells or nutritional de-
Figure 1. The receiver-operating characteristic curve of 
red cell distribution width (RDW) for predicting long- 
-term major adverse cardiac events; AUC — area under 
curve; CI — confidence interval.
Table 2. Effects of various variables on long-term major adverse cardiac events in univariate and multi-
variate Cox regression analyses.
Univariate HR 95% CI P Multivariate HR 95% CI P 
Age 1.03 1.01–1.07 0.03 1.03 0.97–1.09 0.28
Hemoglobin 0.79 0.68–0.93 0.004 0.94 0.59–1.48 0.80
Red cell distribution width 1.84 1.50–2.26 < 0.001 5.26 1.71–16.10 0.004
Hs-CRP 1.06 1.03–1.10 < 0.001 0.98 0.88–1.09 0.76
Admission CK-MB 1.00 1.00–1.01 0.001 1.00 0.99–1.01 0.33
Previously used an ACEI 3.63 1.13–11.66 0.03 2.84 0.44–18.10 0.26
Premature discontinuation  
of clopidogrel therapy
0.23 0.05–1.07 0.06 8.26 0.71–95.91 0.09
After-PCI heart rate 1.02 1.00–1.05 0.03 1.03 0.98–1.07 0.15
LAD lesion 0.44 0.21–0.93 0.03 0.28 0.06–1.35 0.11
Electrocardiographic no-reflow 2.51 1.22–5.16 0.01 2.07 0.46–9.25 0.33
Angiographic failure 2.17 0.93–5.05 0.08 3.07 0.42–22.14 0.26
HR — hazard ratio; CI — confidence interval; hs-CRP — high sensitive C reactive protein; CK-MB — creatine kinase MB; ACEI — angiotensin 
converting enzyme inhibitor; PCI — percutaneous coronary intervention; LAD — left anterior descending
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ficiency such as vitamin B12, iron, and folate, or is 
observed after blood transfusion. In addition, many 
recently published studies reported that increased 
RDW levels are correlated with poor prognosis in 
many acute-chronic cardiac and non-cardiac events 
[7, 9, 14], even in the case of adjustments for 
multiple potential confounders, including anemia. 
In a study by Uyarel et al. [7], high RDW level on 
admission was demonstrated to be an indicator for 
in-hospital and long-term cardiovascular mortality 
in STEMI patients who underwent primary PCI. 
The authors revealed that increased age, Killip 
class > 1, DM, and high RDW were found to be pre-
dictors of cardiovascular mortality [7]. Unlike our 
study, these authors used a retrospective database. 
In the present study, we showed high RDW levels 
were independently associated with increased risk 
for long-term MACE. In a prospective study, Gul 
et al. [15] showed that high RDW levels were as-
sociated with long-term cardiovascular mortality 
in patients with non-STEMI and unstable angina 
pectoris. Van Kimmenade et al. [16] demonstrated 
that high RDW level was an independent indicator 
of 1-year mortality in acute cardiac failure. Similar 
to unstable cardiac events, RDW has been shown to 
have prognostic value also in stable cardiovascular 
conditions. For example, Lappe et al. [2] demon-
strated that RDW was associated with mortality in 
patients with stable CAD. Increased RDW levels 
have been demonstrated to have prognostic im-
plication not only in cardiac conditions, but also 
in many non-cardiac events even in healthy and 
elderly populations [17].
Because RDW is a reflection of conditions that 
increases cardiovascular risk, it is a prognostic 
indicator for both cardiac and non-cardiac events. 
Increased risk related to RDW levels results 
from increased inflammation, oxidative stress 
and neurohormonal transmission both in cardiac 
and non-cardiac events. Like in the case when 
a car which gets out of control may cause undesir-
able conditions, over increased inflammation and 
oxidative stress in our body leads to undesirable 
outcomes. As a result of changes, they exerted on 
erythrocytes; increased inflammation [2, 3], oxida-
tive stress [5] and neurohormonal activation [18] 
lead to different size of erythrocytes to involve 
in the circulation, namely anisocytosis. Possible 
contribution of inflammation to anisocytosis re-
sults from inhibition of the response production 
against erythropoietin, impaired iron metabolism, 
and shortened time of red blood cell survival [19]. 
In addition, it has been found in previous studies 
that inflammatory cytokines suppress the matura-
tion of erythrocytes, therefore immature erythro-
cytes which enter the circulation may accelerate 
erythropoiesis [20]. Previously, we published first 
outcomes of this study and demonstrated that there 
was a good correlation between hs-CRP level, 
which is an important inflammatory marker and 
RDW level on admission [21]. Oxidative stress 
Table 3. Cox regression analysis of major adverse cardiac events (MACE) in overall population for red 
cell distribution width levels.
Outcome Unadjusted Adjusted for Hb Adjusted for Hb and all covariates*
HR (95% CI) P HR (95% CI) P HR (95% CI) P 
MACE 1.84 (1.50–2.26) < 0.001 6.63 (2.82–15.58) < 0.001 5.26 (1.71–16.10) 0.004
*Adjusted for age, high sensitive C-reactive protein, left anterior descending artery lesion, creatine kinase-MB on admission, heart rate after 
percutaneous coronary intervention, previously used an angiotensin converting enzyme inhibitor, premature discontinuation of clopidogrel 
therapy, presence of electrocardiographic no-reflow and angiographic failure in the analysis; HR — hazard ratio; CI — confidence interval;  
Hb — hemoglobin
Figure 2. Kaplan-Meier curves for long-term major ad-
verse cardiac events in patients with red cell distribution 
width (RDW) < 13.85% and RDW ≥ 13.85%.
286 www.cardiologyjournal.org
Cardiology Journal 2016, Vol. 23, No. 3
was suggested as another mechanism of prognostic 
value of RDW [22, 23]. Red blood cells have a pow-
erful antioxidant capacity and function as a primary 
oxidative sink; they are prone to oxidative damage 
which decreases cell survival and they increase the 
release of juvenile erythrocytes into circulation. 
Consequently, we suggest that the link between 
increased oxidative stress and inflammatory activa-
tion and elevated RDW value is closely related with 
prognosis in STEMI. No wonder, it is not enough 
to attribute the association between increased 
RDW level and poor prognosis to the increased 
stress alone. It is well known that there is a close 
relationship between increased levels of RDW 
and many conditions that have prognostic impor-
tance in cardiovascular disease including coronary 
complexity [24], impaired renal function [25], and 
altered hematological features, such as increased 
total blood viscosity which could pose substantial 
changes in the blood flow [26]. Another important 
relationship is the close correlation between in-
creased RDW level and inadequate tissue perfusion 
(no-reflow). With the first outcomes of our previous 
study, we demonstrated that increased RDW levels 
were closely correlated with electrocardiographic 
no-reflow which was an independent predictor of 
mortality after PCI. There are numerous studies 
demonstrating a close correlation between RDW 
and no-reflow, and RDW being a good marker of 
short- and long-term CVE, although evidence for 
the prognostic significance of no-reflow outweighs 
especially in the early period, the correlation be-
tween no-reflow and long-term prognosis remains 
controversial [27]. In fact, in our study we found 
that unlike RDW, electrocardiographic no-reflow 
was not an independent indicator of long-term 
MACE, suggesting that RDW level was a common 
reflection defined not only by no-reflow, but also 
by the other cardiac risk factors.
The pathophysiological mechanistic link which 
drives this correlation remains obscure at the time 
of this study and a more thorough insight into the 
physiological mechanism is needed. Nevertheless, 
theoretically, we believe that inflammatory activa-
tion and oxidative stress, which are accepted as risk 
factors for CVE influence the erythropoiesis and 
thus result in elevated levels of RDW.
Limitations of the study
This study has some possible limitations. 
First, the study was conducted in a single center 
with only a small number of patients. However, 
our study population included homogeneous un-
selected STEMI patients who underwent primary 
PCI; therefore, the real world scenario was able to 
be represented. Second, ∑STR which is an indirect 
method for detecting myocardial perfusion was used. 
Quantitative myocardial contrast echocardiography 
method is able to provide more detailed informa-
tion about tissue perfusion. In addition, myocardial 
blush grade was not assessed due to the fact that 
the optimal cineangiographic frame count setting 
(12.5 Fr/s) was not available. ∑STR measurements 
conventionally obtained from a blinded manual 
were highly reproducible, but measurements to 
be conducted by a digital ECG system with a high-
resolution screen might be more reliable. Third, 
elevated RDW levels are observed in many clinical 
settings including increased red cell destruction 
after transfusion, hemolysis and in the setting of 
ineffective red cell production such as that of iron 
deficiency, vitamin B12 or folate. Levels of RDW 
are also elevated during several clinical conditions 
such as inflammatory bowel diseases, thrombotic 
thrombocytopenic purpura and pregnancy [28–30]. 
Hemoglobin was the only measured factor in this 
study, while other factors were not measured, 
including vitamin B12, iron and folate. Blood trans-
fusion was not carried out in any of our patients, 
while there was no pregnant, inflammatory bowel 
disease, thrombotic thrombocytopenic purpura or 
malnourished patients in this study.
Conclusions
Red cell distribution width is a marker in-
dicating long-term prognosis in STEMI patients 
undergoing primary PCI, which is easily accessible 
and causes no additional cost.
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